MicroRNA-195 as a prognostic factor for cancer survival outcome in China: a meta-analysis
Authors Wang N, Cao Y, Ge X, Nie J, Yu Y, Li Q, Wang F, Miao L
Received 24 February 2019
Accepted for publication 13 July 2019
Published 22 August 2019 Volume 2019:11 Pages 7967—7979
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
Ni Wang,1,* Yang Cao,2,* Xianxiu Ge,1,* Junjie Nie,1 Yang Yu,1 Quanpeng Li,1 Fei Wang,1 Lin Miao1
1Medical Center for Digestive Diseases, Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, People’s Republic of China; 2Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, People’s Republic of China
Correspondence: Lin Miao
Department of Gastroenterology, The Second Affiliated Hospital of Nanjing Medical University, 121 Jiangjiayuan, Nanjing, Jiangsu Province 210011, People’s Republic of China
*These authors contributed equally to this work
Purpose: MicroRNA-195 is dysregulated in different kinds of cancers and plays a pivotal role in tumorigenesis. It may function as a prognostic biomarker for cancers. However, the results from articles were not consistent. This study was designed to validate the prognostic value of microRNA-195 in human tumors.
Methods: We conducted a detailed search on PubMed until December 31, 2018. The quality of these publications was assessed on the basis of a list of key reviews presented by PRISMA statement. The pooled hazard ratios (HR) and pooled odds ratios (OR) of each 95% confidence interval (95% CI) were calculated to assess the effect.
Results: This meta-analysis included 12 studies involving 940 cancer patients to assess the prognostic value of miR-195 in different solid tumors. The results showed that patients with high expression of miR-195 had favorable tumor-node-metastasis (late vs early: pooled OR =0.16, 95% CI: 0.11–0.22, P<0.001), lymph node metastasis (pooled OR =0.25, 95% CI: 0.18–0.35, P<0.001) and distant metastasis (pooled OR =0.26, 95% CI: 0.13–0.52, P<0.001). At the same time, high levels of miR-195 expression were closely correlated with better overall survival (pooled HR =0.46, 95% CI: 0.36–0.58, P<0.001).
Conclusion: Elevated microRNA-195 may serve as a potential biomarker to predict a favorable prognosis for various cancer types in China.
Keywords: biomarker, prognosis, microRNA-195, expression, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]